ADAMTS9 and nonpapillary renal cell carcinoma: Based on this result, we used gain-of-function and loss-of-function assays to determine that ADAMTS9-AS2 suppressed cell proliferation and reduced chemoresistance in ccRCC, implying that ADAMTS9-AS2 may act as a tumor suppressor in ccRCC.